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CURRENT STATUS OF CHLORPROPAMIDE IN
MANAGEMENT OF DIABETES MELLITUS
FRED W . WHITEHOUSE, M.D.*

One year ago in this journal, we reported our experience with tolbutamide in
the management of diabetes mellitus.' Spurred on by the successful clinical application
and low toxicity of tolbutamide, pharmacologists tested a large number of closely
related compounds, seeking one with similar innocuousness but with greater potency
and broader clinical applicability. One such compound, N-propylparachlorobenzenesulfonylurea (chlorpropamide) has demonstrated such activity. We began clinical
trials with this drug in the spring of 1958. This report represents an appraisal of its
clinical effectivity.
Chemically, chlorpropamide differs only slightly from tolbutamide. Figure I
shows the comparative chemical structures. The altered chemical structure accounts
for the greater potency of chlorpropamide. Tolbutamide, with a methyl radical on
the benzene ring, is rapidly inactivated by the liver, while chlorpropamide with a
chlorine atom in place of the methyl group passes through the liver unchanged and
is excreted unaltered by the kidneys. This failure of inactivation by the liver permits
higher and more prolonged blood levels with chlorpropamide than was possible with
tolbutamide. Like tolbutamide, chlorpropamide is completely absorbed from the
gastrointestinal tract. Its pharmacologic activity in no way differs from tolbutamide,
acting primarily on the islets of Langerhans with an associated hepatic effect.
Our experience dates back nine months. Twenty-seven selected patients with
diabetes have been given chlorpropamide. A good hypoglycemic effect occurred in
twenty-three patients. In this group, twenty patients were over 50 years of age at
initiation of oral therapy. Sixteen patients had known diabetes less than five years
and twenty-one less than ten years. Chlorpropamide was used as an insulin substitute
in fourteen patients, as a tolbutamide substitute in four patients, and as an insulin
supplement in one patient. Chlorpropamide was the initial hypoglycemic agent in
four patients. In the fourteen patients on insulin prior to chlorpropamide, thirteen
had been maintained on less than 40 units per day and eight took less than 20 units
per day. In the patient to whom chlorpropamide was given as an insulin supplement,
one gram of the drug and 80 units of isophane (NPH) insulin controlled his diabetes
as well as 200-250 units of insulin daily had previously. Chlorpropamide was substituted for tolbutamide in three cases for investigational purposes only, while in two
patients it was used successfully after secondary failures with tolbutamide.
Figure 1
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Chlorpropamide in Diabetes Mellitus
Four patients were unresponsive to chlorpropamide. Table 1 summarizes their
data. The reader should note the long duration of diabetes and the relatively large
daily insulin dosage required. Three patients had prior primary tolbutamide failures.
None of our patients with primary tolbutamide failures has been successfully controlled with chlorpropamide. Generally speaking, all juvenile (growth-onset) diabetics
are unresponsive to chlorpropamide.
Table 1

Chlorpropamide-Unresponsive patients
Patient

Age

Duration DM Insulin/day

Tolbutamide

L.M.

55y

19y

lOOu

F.M.

30y

17y

50u

primary failure

none

I-M.

65y

3y

36u

primary failure

B.P.

46y

7y

50u

primary failure

Toxicity to tolbutamide is limited to the skin and gastrointestinal tract The
reactions are minor and reversible. Our experience with chlorpropamide has also
been benign. One patient complained of nausea and epigastric pain which was
relieved by decreasing the dosage of the drug. A second patient experienced giddiness
on 1.0 gram per day which disappeared with a decrease to 750 mg per day. This
singular central nervous system reaction occurs with normo — or hyperglycemia
and is related to the size of the daily dose. It is definitely not due to hypoglycemia.
Ataxia may also occur. The incidence of this reaction increases strikingly when
more than 1.0 gram of chlorpropamide is given daily. A third patient noted unsteadiness and an intolerance to alcohol. His drug dosage was 750 mg per day.
Complete symptomatic relief was afforded by the use of insulin. A fourth patient
developed positive liver flocculation tests after six weeks of 250 mg per day. One
month after cessation of the drug, further liver function studies were normal. No
clinical evidence of liver disease ever occurred. This patient is currently well controlled
on diet alone. lezzoni^ reports thirteen cases of jaundice in a group of over 5000
diabetics controlled with chlorpropamide. No deaths from hepatic failure have
occurred. Specimens of liver obtained by needle biopsy show bile stasis and pericholangiolar round cell infiltration, reminding one of the hepatic changes following
chlorpromazine and methyltestosterone. Two deaths in patients on chlorpropamide
have occurred elsewhere from sustained hypoglycemia. Transient leukopenia may
occur and one case of thrombocytopenic purpura has been reported. It is apparent
that the spectrum of toxicity for chlorpropamide is broader than tolbutamide and
falls somewhere between that drug and carbutamide, which was abandoned because
of excessive toxicity.
Table 2 outlines our current indications for the use of chlorpropamide. Any
patient responding to tolbutamide is a favorable candidate for chlorpropamide. However, from a practical standpoint, we are using chlorpropamide only when oral therapy
is desirable and tolbutamide is ineffective. This attitude is reasonable and based
Chlorpropamide (Diabinese) was generously supplied through the courtesy of Dr. Dominic lezzoni
of the Chas. Pfizer Co., Brooklyn, New York.
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upon the comparative toxicity of the two drugs. Chlorpropamide may also be tried
in patients with insulin resistance, in an attempt to lower the daily insulin dose. Any
acute stress eliminates the consideration of chlorpropamide. Chlorpropamide is in
no way a substitute for a good diet, carefully followed. Dietary indiscretions will
rapidly bring about loss of good control. Because of the hepatic side effects, we do
not advise the use of chlorpropamide in patients with known liver disease.

Table 2

Indications for Use of Chlorpropamide
Diet alone insufficient for good control
Oral therapy desirable
Maturity-onset (adult type) diabetes
Absence of stress
Tolbutamide failure

Chlorpropamide is supplied under the trade name, Diabinese, in 100 and 250
mgm tablets. Initiation of therapy is much the same as with tolbutamide except that
an initial loading dose is unnecessary. No test of its effectiveness prior to its use is
available. An initial daily dose of 100 to 500 mg is given. In four to seven days, the
daily dose is increased or decreased by 100 to 250 mg. We have never used more than
500 mg initially nor more than 1000 mg as a daily maintenance dose. The initial dose
should correspond roughly to the degree of estimated insulin deficiency. Depending
upon the clinical and laboratory response, this change in daily dosage is repeated
until a final maintenance dose is reached. Table 3 indicates the average maintenance
dose of 23 successfully controlled patients. When insulin is being replaced, it is
discontinued if less than 20 units per day is used. Otherwise, the insulin dose is
halved until an effect from chlorpropamide is noted; then the insulin is stopped. I f
a large insulin dose is replaced, one can expect a higher maintenance dose of
chlorpropamide. During the period of initiation, serial white blood cell counts are
done. Our practice also includes a serum alkaline phosphatase determination at
bimonthly intervals. The clinician must also be aware of hypoglycemia. Contrary to
tolbutamide, chlorpropamide can result in severe hypoglycemia which may be prolonged. This is a potent hypoglycemic agent. Fortunately we have not experienced
this, though just recently our patient taking a combination of insulin and chlorpropamide
arrived in the Emergency Room comatose with a blood sugar of 40 mg.%. Prompt
response following glucagon occurred.

Table 3

Average maintenance dose (23 patients)
100
250
500
750
1000

mgm.
mgm.
mgm.
mgm.
mgm.

3*
7
6
6**
1

*—one patient now controlled on diet alone
**—one patient now controlled on insulin
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Chlorpropamide in Diabetes fdellitus
Chlorpropamide is an active hypoglycemic agent and can be used when oral
therapy is desirable. As with tolbutamide, the theoretical disadvantage stemming
from chronic islet cell stimulation is present. Our experience in 27 highly selected
diabetics has been good. Twenty-three patients are well controlled (preprandial normoglycemia and aglycosuria). Toxicity has prevented its use in only two patients.
It was disappointing to find that three patients with primary tolbutamide failures were
unsuccessfully regulated with chlorpropamide. This indicates essentially that chlorpropamide gives the clinician greater depth with the use of oral agents but only a slight
increase in breadth. The long duration diabetic and the growth-onset diabetic still
are denied oral therapy. The diabetic under acute stress is denied oral therapy. The
importance of dietary therapy and the miracle of insulin is reaffirmed.
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